What does minimal residual disease (MRD) really mean in multiple myeloma management? This article explores how MRD negativity reflects multiple myeloma progression, is beginning to serve as a key endpoint for FDA approvals, and helps guide treatment decisions.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
IPCE CreditsUp to 0.5 creditsAAPA Category 1 Credit™Up to 0.5 creditsAMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 creditsPharmacyUp to 0.5 credits
MOC types
ABIM — Medical KnowledgeUp to 0.5 points
FDA REMS
No
Qualifies for MIPS
No
Target Specialties
Address:
- 1515 W Cypress Creek Rd
Pricing
100% of listed courses are free
56 of 56 courses listed here are free.
Collected from the provider’s public pages
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Board review / self-assessment
- Credit · Up to 0.5 credits
- MOC · Up to 0.5 points
- Commercial Support
-
ReleasedSep 19, 2025
-
Last day to claim creditDec 1, 2026 7 weeks left
-
Haymarket Medical Education Exploring the Role of Minimal Residual Disease Status in Relapsed/Refractory Multiple Myeloma (Enduring)
-
M3 IME B.V +1 Future Directions in Multiple Myeloma. The Impact of CELMoDs, MRD as a Clinical Endpoint, and the Importance of Shared Decision-Making
-
i3 Health Frontline Decisions in NDMM: Case Discussion on Regimen Selection and MRD-Guided Management
